Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
Background: We assessed the efficacy and safety of sunitinib as the first-line treatment in metastatic renal cell carcinoma (mRCC) patients. The predictors of survival and efficacy in mRCC as identified from previous studies, including the Memorial Sloan Kettering Cancer Center (MSKCC) and the Inter...
Main Authors: | Ong, Teng Aik, Abd Ghafar, Nahjatul Kursyiah, Alip, Adlinda, Yap, Ning Yi, Saad, Marniza |
---|---|
Format: | Article |
Published: |
Medknow Publications
2018
|
Subjects: |
Similar Items
-
The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01) -
Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
by: Ridhima Iyer, et al.
Published: (2017-01-01) -
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
by: Krastan B. Blagoev, et al.
Published: (2013-02-01) -
Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
by: Pavla Bouchalova, et al.
Published: (2021-09-01) -
Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib
by: Leonardo Gomes da Fonseca, et al.
Published: (2014-04-01)